Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s12032-023-02005-w.

Title:
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer | Medical Oncology
Description:
Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The concept of personalized medicine has overshadowed the conventional chemotherapy given to all patients with lung cancer. The targeted therapy is given to a particular population having specific mutations to help in the better management of lung cancer. The targeting pathways for NSCLC include the epidermal growth factor receptor, vascular endothelial growth factor receptor, MET (Mesenchymal epithelial transition factor) oncogene, Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK). SCLC targeting pathway includes Poly (ADP-ribose) polymerases (PARP) inhibitors, checkpoint kinase 1 (CHK 1) pathway, WEE1 pathway, Ataxia Telangiectasia and Rad3-related (ATR)/Ataxia telangiectasia mutated (ATM), and Delta‐like canonical Notch ligand 3 (DLL-Immune checkpoint inhibitors like programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade are also utilized in the management of lung cancer. Many of the targeted therapies are still under development and require clinical trials to establish their safety and efficacy. This review summarizes the mechanism of molecular targets and immune-mediated targets, recently approved drugs, and their clinical trials for lung cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 8,123,628 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, cancer, article, lung, google, scholar, cell, cas, central, nonsmall, small, oncol, clin, inhibitors, immunotherapy, treatment, therapy, targeting, res, med, patients, nonsmallcell, smallcell, targeted, advances, therapeutic, met, mol, targets, nsclc, growth, pathway, pdl, thorac, advanced, rev, mutations, clinical, molecular, transl, wang, yang, nat, inhibition, inhibitor, zhang, review, factor, parp, efficacy,

Topics {✒️}

gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab line-mnsclc-pd-l1-tumor-expression-1 platinum-etoposide versus platinum-etoposide histology-independent ve-basket study month download article/chapter her2/erbb2/neu gene mutations activate anti-tumor immunity targeting pi3k/akt/mtor pathway eml4-alk fusion gene early-stage lung cancer anti-pd-l1/pd-1 immunotherapy anti-pd-1/pd-l1 immunotherapy pd-1/pd-l1 axis inhibitors small-cell lung cancer small-cell lung cancer small-cell lung cancer tead4-driven transcriptional state small-cell lung carcinoma platinum-treated urothelial carcinoma anti–programmed cell death pi3k/akt/mtor pathway high-level met-amplified biomarker-defined disease subsets her2-mutant lung adenocarcinoma reverse-phase protein arrays recently approved drugs anti–programmed death-ligand 1 e2f/rb pathway leads hgf/c-met axis accepted manuscript version approved lag-3 inhibitor dll-immune checkpoint inhibitors patient-derived models egfr-directed monoclonal antibodies full article pdf pd-l1-selected patients covalent cdk7 inhibitor cdk7 inhibitor ypn-005 cell cycle pathways article khadela nivolumab versus docetaxel lung cancer therapy single-arm cohort van aller gs privacy choices/manage cookies lung cancer risk torres-roman js nat rev cancer anti-proliferative activity molecular-targeted therapy

Questions {❓}

  • Angiogenesis: an organizing principle for drug discovery?
  • Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action?
  • Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): does biological rationale meet clinical needs?
  • EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
  • Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
  • Trastuzumab in the treatment of advanced non–small-cell lung cancer: is there a role?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
         description:Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The concept of personalized medicine has overshadowed the conventional chemotherapy given to all patients with lung cancer. The targeted therapy is given to a particular population having specific mutations to help in the better management of lung cancer. The targeting pathways for NSCLC include the epidermal growth factor receptor, vascular endothelial growth factor receptor, MET (Mesenchymal epithelial transition factor) oncogene, Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK). SCLC targeting pathway includes Poly (ADP-ribose) polymerases (PARP) inhibitors, checkpoint kinase 1 (CHK 1) pathway, WEE1 pathway, Ataxia Telangiectasia and Rad3-related (ATR)/Ataxia telangiectasia mutated (ATM), and Delta‐like canonical Notch ligand 3 (DLL-Immune checkpoint inhibitors like programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade are also utilized in the management of lung cancer. Many of the targeted therapies are still under development and require clinical trials to establish their safety and efficacy. This review summarizes the mechanism of molecular targets and immune-mediated targets, recently approved drugs, and their clinical trials for lung cancer.
         datePublished:2023-04-18T00:00:00Z
         dateModified:2023-04-18T00:00:00Z
         pageStart:1
         pageEnd:20
         sameAs:https://doi.org/10.1007/s12032-023-02005-w
         keywords:
            Lung cancer
            Immunotherapy
            Targeted therapy
            Small-cell lung cancer
            Non-small-cell lung cancer
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig7_HTML.png
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
            volumeNumber:40
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Avinash Khadela
               url:http://orcid.org/0000-0001-9914-8539
               affiliation:
                     name:Department of Pharmacology, L. M. College of Pharmacy
                     address:
                        name:Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Humzah Postwala
               affiliation:
                     name:Pharm.D Section, L. M. College of Pharmacy
                     address:
                        name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Deval Rana
               affiliation:
                     name:Pharm.D Section, L. M. College of Pharmacy
                     address:
                        name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hetvi Dave
               affiliation:
                     name:Pharm.D Section, L. M. College of Pharmacy
                     address:
                        name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ketan Ranch
               affiliation:
                     name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy
                     address:
                        name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sai H. S. Boddu
               affiliation:
                     name:Ajman University
                     address:
                        name:Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
      description:Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The concept of personalized medicine has overshadowed the conventional chemotherapy given to all patients with lung cancer. The targeted therapy is given to a particular population having specific mutations to help in the better management of lung cancer. The targeting pathways for NSCLC include the epidermal growth factor receptor, vascular endothelial growth factor receptor, MET (Mesenchymal epithelial transition factor) oncogene, Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK). SCLC targeting pathway includes Poly (ADP-ribose) polymerases (PARP) inhibitors, checkpoint kinase 1 (CHK 1) pathway, WEE1 pathway, Ataxia Telangiectasia and Rad3-related (ATR)/Ataxia telangiectasia mutated (ATM), and Delta‐like canonical Notch ligand 3 (DLL-Immune checkpoint inhibitors like programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors and Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade are also utilized in the management of lung cancer. Many of the targeted therapies are still under development and require clinical trials to establish their safety and efficacy. This review summarizes the mechanism of molecular targets and immune-mediated targets, recently approved drugs, and their clinical trials for lung cancer.
      datePublished:2023-04-18T00:00:00Z
      dateModified:2023-04-18T00:00:00Z
      pageStart:1
      pageEnd:20
      sameAs:https://doi.org/10.1007/s12032-023-02005-w
      keywords:
         Lung cancer
         Immunotherapy
         Targeted therapy
         Small-cell lung cancer
         Non-small-cell lung cancer
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02005-w/MediaObjects/12032_2023_2005_Fig7_HTML.png
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
         volumeNumber:40
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Avinash Khadela
            url:http://orcid.org/0000-0001-9914-8539
            affiliation:
                  name:Department of Pharmacology, L. M. College of Pharmacy
                  address:
                     name:Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Humzah Postwala
            affiliation:
                  name:Pharm.D Section, L. M. College of Pharmacy
                  address:
                     name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Deval Rana
            affiliation:
                  name:Pharm.D Section, L. M. College of Pharmacy
                  address:
                     name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hetvi Dave
            affiliation:
                  name:Pharm.D Section, L. M. College of Pharmacy
                  address:
                     name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ketan Ranch
            affiliation:
                  name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy
                  address:
                     name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sai H. S. Boddu
            affiliation:
                  name:Ajman University
                  address:
                     name:Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
      volumeNumber:40
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Department of Pharmacology, L. M. College of Pharmacy
      address:
         name:Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, India
         type:PostalAddress
      name:Pharm.D Section, L. M. College of Pharmacy
      address:
         name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
         type:PostalAddress
      name:Pharm.D Section, L. M. College of Pharmacy
      address:
         name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
         type:PostalAddress
      name:Pharm.D Section, L. M. College of Pharmacy
      address:
         name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
         type:PostalAddress
      name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy
      address:
         name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy, Ahmedabad, India
         type:PostalAddress
      name:Ajman University
      address:
         name:Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Avinash Khadela
      url:http://orcid.org/0000-0001-9914-8539
      affiliation:
            name:Department of Pharmacology, L. M. College of Pharmacy
            address:
               name:Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, India
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Humzah Postwala
      affiliation:
            name:Pharm.D Section, L. M. College of Pharmacy
            address:
               name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Deval Rana
      affiliation:
            name:Pharm.D Section, L. M. College of Pharmacy
            address:
               name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Hetvi Dave
      affiliation:
            name:Pharm.D Section, L. M. College of Pharmacy
            address:
               name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Ketan Ranch
      affiliation:
            name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy
            address:
               name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Sai H. S. Boddu
      affiliation:
            name:Ajman University
            address:
               name:Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, India
      name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
      name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
      name:Pharm.D Section, L. M. College of Pharmacy, Ahmedabad, India
      name:Department of Pharmaceutics and Pharm. Technology, L. M. College of Pharmacy, Ahmedabad, India
      name:Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(494)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.23s.